Nasdaq:US$31.07 (-0.43) | HKEX:HK$49.70 (-1.10) | AIM:£4.65 (+0.06)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Sustainability
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
Careers
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Sustainability
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
Careers
News & Presentations
Hutchmed
| News & Presentations
News & Press Releases
12 Jan 2022
HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia
Read more
10 Jan 2022
HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China
Read more
20 Dec 2021
HUTCHMED Included in FTSE Russell Indexes
Read more
14 Dec 2021
HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meeting
Read more
Scientific Publications
12 Dec 2021
ASH 2021: Preliminary Results from a Phase I Study of HMPL-523, a Selective, Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma.
Read more
3 Nov 2021
NANETS 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors
Read more
17 Sep 2021
ESMO2021: A Phase Ib/II Study of Fruquintinib in Combination with Tislelizumab in Patients with Advanced Triple Negative Breast Cancer
Read more
22 Jun 2021
The Lancet Respiratory Medicine: Savolitinib in Chinese NSCLC patients harbouring MET exon 14 skipping alterations
Read more
Mailing List Sign-up
If you would like to be kept up to date with the latest news of HUTCHMED, please sign up to our mailing list . We will deliver the relevant material directly to your email box as soon as it becomes available online.